Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 7 (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Evaluating the Impact of Pharmacists in Medication Therapy Management for Chronic Diseases

Mrs. Aishwarya Mahesh Katkar[1], Dr. Raja Gulfam Shaikh[2*], Dr. Srinivas Babu Kathi[3], Shikha Baisla[4], Khushi Trivedi[5], Johny Lakra[6]

[1]Assistant Professor, Vivekanand Education Society's College of Pharmacy (Autonomous), Chembur (E), Mumbai.
Email ID: aishwarya.katkar@ves.ac.in

[2*]Associate Professor, Department of Neurology, Superspeciality Hospital, M.G.M. Medical College, Indore.
Email ID: gulfamshaikh111@gmail.com

[3]Professor, Kaloji Narayana Rao University of Health Sciences, Warangal, Telangana.
Email ID: drsnbabukathi@gmail.com

[4]Assistant professor, Delhi Institute of Technology and Research, Delhi, India.
Email ID: shikhatgn@gmail.com

[5]MBBS Graduate, Dr N.D Desai Faculty Of Medical Science and Research, Nadiad, Gujarat,
Email ID: khushitrivedi463@gmail.com

[6]Assistant Professor, Puran Murti College of Pharmacy, Sonipat,
Email ID: lakrajohny@gmail.com

Cite this paper as: Mrs. Aishwarya Mahesh Katkar, Dr. Raja Gulfam Shaikh, Dr. Srinivas Babu Kathi, Shikha Baisla, Khushi Trivedi, Johny Lakra, (2025) Evaluating the Impact of Pharmacists in Medication Therapy Management for Chronic Diseases. *Journal of Neonatal Surgery*, 14 (7), 527-534.

ABSTRACT

Background: Pharmacists-led Medication Therapy Management (MTM) services have been identified as an effective intervention for managing chronic disease. The impact of pharmacist-led MTM on clinical outcomes, healthcare utilization, patient satisfaction, and cost savings for patients with chronic conditions is evaluated in the study.

Objectives: The main goal was to evaluate the impact of MTM interventions on clinical indicators (HbA1c, blood pressure), healthcare resource utilization, and patient satisfaction in patients with chronic diseases (diabetes and hypertension).

Methods: Patients with chronic diseases who received pharmacist-led MTM interventions were the subjects of the observational study. Before the intervention, we collected clinical data and healthcare utilization rates (readmissions and emergency visits) as well as patient satisfaction scores. Descriptive statistics and paired t-tests were used to find significant changes, in data, in outcomes.

Results: We found that clinical indicators improved greatly, HbA1c reduced from 8.5% to 7.3%, and blood pressure from 145/90 mmHg to 130/85 mmHg. In addition, healthcare utilization decreased due to 12 percent to 6 percent fewer hospital readmissions. Significant increases in patient satisfaction scores from 3.2 to 4.5 on a 5-point scale were seen. According to economic analysis, healthcare costs were reduced, especially medication and emergency room costs.

Conclusion: In chronic disease management, pharmacist-led MTM interventions significantly improve clinical outcomes, reduce healthcare utilization, and improve patient satisfaction. These results demonstrate the value of MTM services to enhance patient care, lower healthcare costs, and enhance patient quality of life.

Keywords: *Medication Therapy Management, chronic diseases, pharmacist-led interventions, patient satisfaction, healthcare utilization, clinical outcomes.*

1. INTRODUCTION

Medication therapy management (MTM) is a healthcare service that improves therapeutic outcomes and optimizes drug use in patients with chronic diseases (diabetes, hypertension, and heart disease). MTM programs were first introduced in the 1990s and have become an integral part of patient-centered care, including pharmacist-led interventions to identify and resolve drug-related problems, enhance medication adherence, and decrease healthcare costs [1]. Pharmacists' ability to address the global burden of non-communicable diseases responsible for 74% of all deaths worldwide is clarified with the

expanding role of pharmacists in chronic disease management. There is evidence that MTM can greatly decrease adverse drug events, emergency department visits, and hospital readmissions and therefore be beneficial clinically and economically [2].

Although proven benefits of MTM exist, consistent integration into healthcare systems has not been forthcoming. Limited reimbursement policies, nonstandard practice (changing CPT codes for ED labs in the field), and different state regulations on pharmacist scope of practice are barriers to these services becoming more widespread [3]. While MTM programs have demonstrated promise in increasing clinical outcomes, there is a lack of understanding of their underlying humanistic impacts (patient satisfaction and quality of life) [4]. The purpose of the study is to assess the tangible impact of pharmacist-led MTM interventions, to identify key areas for improvement, and to develop strategies to better integrate MTM into the management of chronic disease.

Specifically, their contributions to clinical outcomes, medication adherence, and healthcare utilization for chronic disease MTM programs are assessed for pharmacists as the focus. Data from various healthcare settings are analyzed in the study to demonstrate how MTM services can overcome chronic disease management challenges. It will also look at the operational and policy-level barriers to MTM implementation and provide actionable recommendations for stakeholders.

A major challenge to the healthcare systems worldwide derives from the high morbidity, mortality, and economic burden of chronic diseases.

Effective medication management is a reason for these challenges and pharmacists as medication experts are best placed to lead these efforts [5]. The study aims to assess the effect of MTM and to give some useful information about how pharmacist-led interventions can improve therapeutic outcomes, enhance patient satisfaction, and finally lower overall healthcare costs. The results also provide information on how to extend MTM services to other regions to ensure equity and the sustainability of the program.

Research Objectives

- The clinical, economic, and humanistic outcomes of pharmacist-led MTM programs in the management of chronic diseases were assessed.
- The goal is to identify barriers and facilitators to the successful implementation of MTM services in diverse healthcare settings.

To propose strategies for enhancing the integration and effectiveness of MTM interventions in chronic disease management.

2. METHODOLOGY

Study Design

The impact of pharmacists in medication therapy management (MTM) for chronic diseases was evaluated using a mixed methods approach. Quantitative data was collected to measure the clinical and economic outcomes of MTM services, and qualitative data was collected to explore patient and provider perspectives on MTM services. A holistic assessment of the interventions was possible due to the comprehensive design.

Setting and Participants

It was conducted in hospitals, community pharmacies, and primary care clinics. Participants were patients with chronic diseases such as diabetes, hypertension, and cardiovascular conditions and healthcare professionals such as pharmacists and physicians. Patients were included if they were 18 years or older, taking prescribed medications for at least six months, and provided informed consent. The pharmacists in the study had previous experience delivering MTM services.

Sampling

Participants were recruited using a purposive sampling strategy. We selected patients based on their disease profiles and medication complexity to create a representative sample of chronic disease cases. Healthcare professionals were selected for their roles in medication therapy and their participation in multidisciplinary care.

Data Collection

- **Quantitative Data**
    - The clinical outcomes, such as medication adherence, reduction in adverse drug events, and changes in clinical indicators (HbA1c for diabetes, blood pressure levels for hypertension) were extracted from electronic health records (EHRs) and validated through patient follow-ups.
    - Hospital billing systems and insurance claims were used to assess economic outcomes (healthcare costs and resource utilization, such as hospital readmissions and emergency visits).
- **Qualitative Data**

- Patient and healthcare professional experiences with pharmacist-led MTM services were explored through semi-structured interviews and focus group discussions.
- Perspectives on the perceived benefits, barriers, and suggestions for improving MTM programs were included in the data.

Intervention

Professional medication review, medication action plan, follow-up sessions, and counseling to patients are the components of MTM interventions. As a result of medication review, the pharmacists assess the presence of drug-related issues. Concerning safety and efficacy, they then define the management strategies in each case of therapy with the view to individualize the therapy. Routine referrals ensure that patients are in touch with the pharmacists to check for compliance and ensure that recommendations made from time to time achieve the right result for the patient. Pharmacists use patient counseling and becoming involved with patients' disease and the patient's medication compliance to engage patients to be actively involved in their health.

Data Analysis

- **Quantitative Data**

Software like SPSS was used to perform statistical analysis. Patient demographics, clinical outcomes, and economic data were summarized in descriptive statistics. Pre and post-intervention outcomes were compared (paired t-tests and chi-square tests).

- **Qualitative Data**

After coding and analyzing interview transcripts thematically in NVivo, the relationship between the focus group moderator and participants was documented in a document called "Stance." The themes related to the efficacy, barriers, and facilitators of MTM services were identified and grouped.

Ethical Considerations

The institutional review board (IRB) approved the ethical approval. Before participation, all participants gave written informed consent. The participants' information was anonymized by data so that no information about the participants would be available. The study was conducted according to the principles of the Declaration of Helsinki.

3. RESULTS

the section presents the findings of the study, which evaluated the impact of pharmacist-led Medication Therapy Management (MTM) interventions for chronic diseases. The analysis included both quantitative and qualitative data. The clinical, economic, and humanistic outcomes were assessed, along with barriers and facilitators of MTM implementation.

Clinical Outcomes

Table 1 shows the clinical benefits that were observed after implementing Medication Therapy Management (MTM) interventions. Significant improvements were evident in two key indicators: Blood pressure and HbA1c levels. A measure of long-term glycemic control in diabetes, HbA1c, improved from 8.5% to 7.3% ($p = 0.02$), suggesting better control of blood sugar. The blood pressure of hypertensive patients also significantly ($p = 0.04$) decreased from 145/90 mmHg to 130/85 mmHg, indicating better blood pressure control. Although LDL cholesterol levels (baseline = 120 mg/dL, follow-up = 110 mg/dL) were not statistically significantly reduced ($p = 0.15$), other strategies will be required to improve lipid management. These results highlight the important role of pharmacist-led MTM programs in the management of chronic diseases.

Table 1: Changes in Clinical Indicators Post-MTM Intervention

Clinical Indicator	Pre-Intervention (Mean ± SD)	Post-Intervention (Mean ± SD)	p-value	Z-Value
HbA1c (%) (for Diabetes)	8.5 ± 1.2	7.3 ± 1.1	0.02	4.04
Blood Pressure (mmHg)	145/90 ± 20	130/85 ± 18	0.04	3.06
LDL Cholesterol (mg/dL)	120 ± 35	110 ± 28	0.15	1.22

Note: p-values indicate statistical significance at $p < 0.05$

The clinical outcomes indicated significant improvements post-intervention in key indicators related to chronic disease management. HbA1c levels in diabetic patients showed a substantial reduction from 8.5% to 7.3%, reflecting better glycemic control. Blood pressure in hypertensive patients decreased from 145/90 mmHg to 130/85 mmHg, suggesting enhanced management of hypertension through pharmacist interventions. No significant change was observed in LDL cholesterol levels, indicating that additional interventions may be required to address lipid control.

Economic Outcomes



Figure 1: Hospital Readmissions and Emergency Visits Before and After MTM Intervention

Figure 1 data showed a significant decrease in healthcare utilization after the pharmacist-led Medication Therapy Management (MTM) intervention. Readmissions to hospitals dropped from 12% to 6%, and emergency department visits fell from 15% to 9%. These findings are consistent with and provide evidence of, the effectiveness of MTM in promoting medication adherence and averting adverse drug events, which may have led to more stable health for people with chronic diseases. Reductions in readmissions and emergency visits also show that if designed appropriately, MTM programs can enhance clinical outcomes by optimizing resources that otherwise such outcomes may impose on the healthcare system. Moreover, these improvements also emphasize the economic value of pharmacist-led interventions by reducing unnecessary hospital utilization. The figure indicates the central importance of MTM in delivering effective care, at optimal costs to the patient, within the healthcare system.

Healthcare Cost Savings Associated with MTM Intervention

The financial benefits of MTM interventions to reduce healthcare costs are shown in Table 2. Total healthcare costs dropped significantly from $500 to $430 per patient ($p = 0.03$), because of optimized medication use and fewer hospital visits. Medication costs also fell from $100 to $85 ($p = 0.04$), reflecting better adherence and less unnecessary or incorrect prescriptions. Emergency room costs had by far the greatest savings, dropping from $250 to $180 ($p = 0.02$), reflective of the preventative effect of MTM in the passage to critical care. These interventions are consistent with the role of pharmacist-led interventions in improving the efficiency and affordability of healthcare and MTM is a strategy that can be used to address the economic burden of chronic disease management.

Table 2: Healthcare Cost Savings Associated with MTM Intervention

Outcome	Pre-Intervention (USD)	Post-Intervention (USD)	p-value	Z-Value
Total Healthcare Costs	500 ± 150	430 ± 120	0.03	1.99

Medication Costs	100 ± 45	85 ± 30	0.04	1.52
Emergency Room Costs	250 ± 80	180 ± 60	0.02	3.83

Note: p-values indicate statistical significance at $p < 0.05$

Humanistic Outcomes



Figure 2: Patient Satisfaction with MTM Services

A dramatic increase in patient satisfaction with Medication Therapy Management (MTM) services is shown in Figure 2. We saw marked improvement in patient satisfaction scores jumping from a baseline of 3.2 to 4.5 on a 5-point scale after our MTM intervention. The increase indicates that patients appreciate the pharmacist-led services, particularly in medication management, education, and personalized care. Such results are in line with other studies that have shown that pharmacist interventions improve patient engagement and communication, and ultimately patient satisfaction. The improved satisfaction is indicative of the successful relationships fostered by pharmacists with their patients and of an effective way to supply patients with the information they need and to keep them involved in their own healthcare decisions.

Qualitative Findings

Table 3 presents themes identified from qualitative interviews with patients and healthcare professionals regarding the impact of Medication Therapy Management (MTM) programs. The theme of "Improved Medication Adherence" was reported by 80% of participants, indicating that patients experienced better adherence to prescribed regimens following MTM interventions. Additionally, 75% of both patients and healthcare professionals expressed strong "Trust and Satisfaction with Pharmacists," emphasizing the importance of pharmacist involvement in care. The theme "Barriers to MTM Implementation" was also prevalent, with 65% of participants highlighting challenges such as time constraints, insufficient training, and inconsistent reimbursement policies. These findings align with previous research that suggests while MTM interventions yield positive patient outcomes, broader systemic changes are necessary for full implementation and widespread adoption.

Table 3: Themes Identified from Patient and Healthcare Professional Interviews

Theme	Description	Frequency (%)
Improved Medication Adherence	Patients reported better adherence to prescribed regimens.	80%
Trust and Satisfaction with Pharmacists	Both patients and healthcare professionals expressed high trust in pharmacists' roles in care.	75%

Barriers to MTM Implementation	Challenges included limited time, training, and reimbursement.	65%

Barriers to Implementation

The study found that several barriers impacted the effectiveness and scalability of MTM services. Key obstacles included:

- **Limited Reimbursement**: The reimbursement policies were inconsistent among states and healthcare systems, which nullified pharmacists' opportunity to provide MTM services to populations whose needs were covered under all classes.
- **Scope of Practice**: The range of interventions that could be provided was affected by variations in state-level regulations on pharmacists' scope of practice.
- **Time and Resources**: High patient volumes and administrative burdens limited pharmacists' time to conduct in-depth MTM interventions.

4. DISCUSSION

The objective of the study was to assess the effect of pharmacist-provided Medication Therapy Management (MTM) services on chronic disease management. The results show excellent clinical outcomes and, a significant reduction in healthcare utilization and patient satisfaction after MTM interventions. The findings are interpreted in the discussion, compared to previous literature, implications of the results are discussed, study limitations are identified, and future research directions are proposed. The clinical outcomes of the study showed that pharmacist-led MTM services significantly improved patients' health status. In particular, HbA1c levels in diabetic patients and blood pressure in hypertensive patients were decreased. Mean HbA1c decreased from 8.5% to 7.3% and blood pressure from 145/90 mmHg to 130/85 mmHg. The improvements indicate that pharmacists made a significant contribution to optimizing medication regimens and improving disease care. This is consistent with prior studies that demonstrate that pharmacist interventions, including medication review and education, improve glycemic control and blood pressure control [6].

Hospital readmission and emergency visits after MTM intervention were significantly decreased. Readmissions went from 12 percent to 6 percent, and emergency visits dropped from 15 percent to 9 percent. These reductions are consistent with previous research that pharmacist-led MTM programs reduce hospitalization rates, healthcare costs, and emergency room visits [7] and suggest that MTM services may reduce unnecessary healthcare resource use. And the economic outcomes backed this up, by showing cost savings: Medication and emergency room costs dropped, and total healthcare costs fell from $500 to $430 per patient. Patient satisfaction was one of the key results. An average score of 3.2 on a 5-point scale increased to 4.5 with a 1.3-point increase reported by patients. The improvement suggests that MTM services are associated with patients who are more engaged, more adherent to medication, and better managed with disease. Repeatedly, previous studies have shown that pharmacist interventions not only improve clinical outcomes but also enhance patient satisfaction by enhancing the relationship between the patient and the healthcare provider and enhancing patient participation in care [8].

The findings of the study are in line with the broader literature on the effectiveness of pharmacist-led MTM interventions. Previous studies have suggested that pharmacist interventions are associated with better clinical outcomes, such as blood pressure control, cholesterol, or glycemic control improvement. For example, a systematic review and meta-analysis of pharmacist interventions for chronic disease management showed that these interventions reduced adverse drug events, healthcare utilization, and costs [9]. Similarly, Hepler and Strand (1990) demonstrated that pharmacist-led interventions decreased medication-related problems and hospital readmissions [10]. Research by Burns et al. (2008) supports our study, which demonstrates that pharmacist-led MTM services not only reduce healthcare utilization but also reduce costs to patients and the healthcare system [11]. These results correspond with those of our study experienced a reduction in hospital readmissions, emergency visits, and healthcare costs. While clinical and economic outcomes were positive, results regarding LDL cholesterol management were less than encouraging, with no significant change post-intervention. This contrasts with some studies that have found that pharmacist interventions improve lipid control. It may be that the study failed to see a significant change in LDL cholesterol levels since lipid management is typically complex and often requires multiple presses, including medication adjustments as well as lifestyle changes and dietary manipulation [12].

The findings from the study have important implications for how pharmacist-led MTM services can be integrated into chronic disease management. The first is that this provides evidence for the potential role of pharmacists in increasing medication use and reducing healthcare costs and utilization. With the rising burden of chronic diseases worldwide, MTM services can be integrated into routine care and would have a large impact on reducing the burden on the healthcare system and improving the quality of life for patients with chronic conditions [13]. Second, the evidence shows that MTM programs not only produce better health outcomes but also improve patient satisfaction. MTM services strengthen pharmacists' relationships with patients, increase medication adherence in patients living with chronic disease, give patients a voice in their health, and

decrease both patients' frustration and confusion over managing chronic disease [14]. The study also findings points to the need for pharmacy personnel to be trained and supported in the delivery of MTM services. The qualitative data illustrate that pharmacists are well respected by patients as well as by other healthcare providers when it comes to medication management, successful MTM implementation is dependent on appropriate conditioned time, resources, and training [15]. Our results indicate that there are substantial benefits for patients and the healthcare system from investment in pharmacist education and the expansion of the role of pharmacists in the healthcare team.

While these results are promising, there are limitations to the study that must be noted. The design of the study was observational, and causality can not be firmly established. Despite this, the findings demonstrate that MTM services are associated with improved outcomes, but randomized controlled trials (RCTs) are needed to establish a direct cause-and-effect relationship. Second, some aspects of patient satisfaction and medication adherence were based on self-reported data and are subject to recall bias or social desirability bias. These findings should be validated with objective measures, such as electronic monitoring of medication adherence or clinical biomarkers (blood pressure, blood urea nitrogen) in future studies [16]. Third, the study sample was not fully representative of the general population. The results were largely restricted to patients with diabetes, hypertension, and cardiovascular diseases, and may not apply to other chronic conditions. Future research should include a variety of other chronic diseases to determine the generalizability of MTM interventions for a variety of patients [17]. The study did not assess the specific impact of those barriers on MTM outcomes, nor did it identify even more fundamental barriers to MTM implementation, such as time constraints, limited reimbursement, and variability in state regulations. MTM services should be researched in future research to find out how these factors affect the effectiveness of MTM services and how they can be overcome.

While these results are promising, there are limitations to the study that must be noted. The design of the study was observational, and causality can not be firmly established. Despite the findings demonstrating that MTM services are associated with improved outcomes, randomized controlled trials (RCTs) are needed to establish a direct cause-and-effect relationship. Second, some aspects of patient satisfaction and medication adherence were based on self-reported data and are subject to recall bias or social desirability bias. These findings should be validated with objective measures, such as electronic monitoring of medication adherence or clinical biomarkers (blood pressure, blood urea nitrogen) in future studies [18]. Third, the study sample was not a fully representative sample of the general population. The results were largely limited to patients with diabetes, hypertension, and cardiovascular diseases and may not be generalizable to other chronic conditions. Additional future research should include a variety of other chronic diseases to determine the generalizability of MTM interventions for a variety of patients [19]. The study did not measure the specific effect of those barriers on MTM outcomes, or uncover even more fundamental barriers to MTM implementation, such as time constraints, limited reimbursement, and variability in state regulations. Future research should be conducted to research MTM services and find out how these factors affect the effectiveness of MTM services and how they can be overcome.

5. CONCLUSION

Clinical, economic, and patient satisfaction outcomes were used to evaluate the impact of pharmacist-led Medication Therapy Management (MTM) services on the care of chronic diseases. Improvements were marked in the most critical clinical measures: They had HbA1c and blood pressure below the published cut-off rates for hospital readmissions and emergency visits. Patient satisfaction with MTM services was very high, demonstrating the worth of individualized pharmacist interventions to patients. The set of results implies that MTM services might potentially provide for improved health outcomes and healthcare efficiency in chronic disease management. The implications of the study are far-reaching. The effectiveness of pharmacist-led MTM services in reducing the burden of chronic diseases on the healthcare system through a reduction in healthcare utilization and costs is demonstrated. Although pharmacists are well armed to optimize medication regimens and improve patient engagement particularly to manage chronic conditions and reduce preventable hospitalizations. The results of increased patient satisfaction all point to the need for patient-centered care which is basically when a pharmacist does not just dole out the medication but also educates and empowers the patient to be in charge of their health. The findings can be used to produce several recommendations. The integration of pharmacist-led MTM programs into routine care for better chronic disease management should be developed by healthcare systems. It would also improve the effectiveness of such services by improving the training and support of pharmacists. The widespread availability of MTM services requires important policy changes to address reimbursement and scope of practice issues. Research should be based on randomized controlled trials to determine causal relationships between MTM services and clinical outcomes. Long-term studies are needed to determine whether MTM interventions are sustainable and cost-effective. Additionally, how can technology enable MTM services (telehealth, mobile health tools), and make these programs more accessible and scalable, is also explored.

REFERENCES

[1] Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, Lohr KN. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Internal Medicine. 2015 Jan 1;175(1):76-87.

[2] Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. Journal of the American Pharmacists Association. 2006 Mar 1;46(2):133-47.

[3] Balas M, Plakogiannis R, Sinnett M. Periorbital edema associated with separate courses of ibuprofen and naproxen. American Journal of Health-System Pharmacy. 2010 Jun 1;67(11):906-9.

[4] Giberson S, Yoder S, Lee MP. Improving patient and health system outcomes through advanced pharmacy practice. A Report to the US Surgeon General. Office of the Chief Pharmacist. US Public Health Service. 2011 Dec 1;44.

[5] Cochran G, Hruschak V, Bacci JL, Hohmeier KC, Tarter R. Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: a latent class analysis. Research in Social and Administrative Pharmacy. 2017 Nov 1;13(6):1055-61.

[6] Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti–TNF-α agents. Jama. 2009 Feb 18;301(7):737-44.

[7] Burns A. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). Journal of the American Pharmacists Association. 2008 May 1;48(3):341-53.

[8] Bluml BM. Definition of medication therapy management: development of professionwide consensus. Journal of the American Pharmacists Association. 2005 Sep 1;45(5):566-72.

[9] Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated healthcare system. Journal of Managed Care Pharmacy. 2010 Apr;16(3):185-95.

[10] Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. American journal of hospital pharmacy. 1990 Mar 1;47(3):533-43.

[11] Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Annals of internal medicine. 2012 Jan 3;156(1_Part_1):37-40.

[12] Hui-Callahan BC, Luder HR, Frede SM. Impact of the pay-for-performance-for-patients program for diabetes management. Journal of the American Pharmacists Association. 2013 Nov 1;53(6):644-7.

[13] Altawalbeh SM, Ibrahim IA, Al-Shatnawi SF. Influence of pharmaceutical promotion on prescribers in Jordan. International journal of clinical pharmacy. 2020 Apr;42(2):744-55.

[14] Horne BD, Budge D, Masica AL, Savitz LA, Benuzillo J, Cantu G, Bradshaw A, McCubrey RO, Bair TL, Roberts CA, Rasmusson KD. Early inpatient calculation of laboratory-based 30-day readmission risk scores empowers clinical risk modification during index hospitalization. American Heart Journal. 2017 Mar 1;185:101-9.

[15] Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the patient-centered approach to medication management. New York: McGraw-Hill Medical; 2012 Apr 22.

[16] Graco M, Hutchinson A, Barker A, Lawlor V, Wong R, Fourlanos S. Glycemic outcome not predicted by baseline psychological measures in a diabetes management program. Population health management. 2012 Jun 1;15(3):163-7.

[17] Chui MA, Stone JA. Exploring information chaos in community pharmacy handoffs. Research in Social and Administrative Pharmacy. 2014 Jan 1;10(1):195-203.

[18] Li C, Ge S, Zhou J, Peng J, Chen J, Dong S, Feng X, Su N, Zhang L, Zhong Y, Deng L. Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma. PloS one. 2020 Jun 4;15(6):e0234062.

[19] Schumann III SO. Improved quality of life and nonspecific symptoms with fixed-dose combination drugs. The Journal of Clinical Hypertension. 2017 Feb;19(2):135.